Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dersimelagon - Mitsubishi Tanabe Pharma

Next Previous
X
Search
Drug Profile

Dersimelagon - Mitsubishi Tanabe Pharma

Alternative Names: [14C] MT-7117; Dersimelagon; MT-7117; MT-7117-MB

Latest Information Update: 22 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Carboxylic acids; Cyclopentanes; Fluorinated hydrocarbons; Phenyl ethers; Piperidines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Melanocortin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic protoporphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Erythropoietic protoporphyria
  • Phase II Diffuse scleroderma
  • No development reported Autoimmune disorders

Most Recent Events

  • 12 Jun 2024 Efficacy data from a phase II trial in Diffuse scleroderma presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 14 Feb 2024 Mitsubishi Tanabe Pharma America completes a phase II trial in Diffuse scleroderma (In the elderly, In adults) in USA, Belgium, Canada, Germany, Italy, Spain, Poland and the United Kingdom (PO) (NCT04440592) (EudraCT2020-000134-17)
  • 11 Dec 2023 Phase-III clinical trials in Erythropoietic protoporphyria (In adolescents, In adults, In the elderly) in USA (PO) (NCT06144840)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top